Primo Capital

Primo Capital is a Milan-based early-stage venture fund recognized as one of the more visible Italian platforms backing technology companies with a thesis-driven approach. Healthcare interest spans digital health and medical devices, with the firm presenting itself as an operationally engaged investor that works closely with founders post-investment. There is no specifically marketed artificial intelligence thesis, although the broader portfolio includes software and digital businesses where AI components may appear. Limited public information is available about individually named partners attached to specific healthcare deals beyond the firm’s general team disclosures.

Primo Capital invests at Pre-Seed, Seed, and Series A, with check sizes commonly in the one to five million dollar range. Geographic concentration is firmly Italy, with selective European participation in cross-border syndicates where Italian founders expand abroad. The fund leads or co-leads early rounds and is willing to take an active board role, reflecting its hands-on operating posture. Pacing is consistent with a Southern European early-stage manager that maintains a steady deployment rhythm and reserves capital for follow-ons inside its existing portfolio.

For founders, Primo Capital is well suited when building an Italian digital health or medical device company that will benefit from a domestic investor capable of opening commercial doors, navigating local regulators, and structuring follow-on rounds with European co-investors. Diligence emphasizes founder quality, market sizing, and clarity of go-to-market motion. Founders should expect a working relationship that includes regular operational touchpoints rather than passive board-meeting capital, and should be prepared to discuss product development, hiring plans, and commercial milestones in concrete terms during the diligence process.